Behavioral Activation and Risk Reduction for Stimulant Use Among Sexually Active Young Gay/Bisexual Minority Men (IMPACT)

a study on HIV/AIDS

Eligibility: for males ages 16-24 (full criteria)
Healthy Volunteers: healthy people welcome
Location: at UCLA
Dates: study started October 2024
completion around December 2028
Principal Investigator: by Matthew Mimiaga, ScD, MPH (ucla)

Matthew Mimiaga

Description

Summary

The use of behavioral intervention to reduce stimulant use and concurrent HIV sexual transmission risk

Official Title

Hybrid Type 2 Effectiveness-Implementation Trial of Status Neutral, Integrated Behavioral Activation and Risk Reduction Intervention for Stimulant Use Among Sexually Active Young Gay/Bisexual Sexual Minority Men (Project IMPACT)

Details

IMPACT is a Human Immunodeficiency Virus (HIV) status-neutral, behavioral intervention to reduce stimulant use and concurrent HIV sexual transmission risk. This study will evaluate the effectiveness of IMPACT and determine feasibility of implementing IMPACT across various settings for translation into real-world practice using a hybrid effectiveness-implementation design.

The IMPACT intervention includes 10 sessions: 2 intervention sessions of HIV risk reduction (RR), 1 session focused on orienting and rationale of behavioral activation (BA), 6 sessions integrating BA and RR-including pre-exposure prophylaxis (PrEP) or antiretroviral therapy (ART) and HIV care-and 1 final session on relapse prevention.

The enhanced Standard of Care (eSOC) group includes two HIV RR intervention sessions.

Keywords

HIV, HIV Sexual Transmission Risk, Behavioral Activation, Risk Reduction Intervention, Stimulant Use, IMPACT, eSOC

Eligibility

You can join if…

Open to males ages 16-24

Age 16-24 years, inclusive, at enrollment
Assigned male at birth
Identifies as a cisgender boy or man
Self-reports condomless anal sex (CAS) with another boy/man-receptive or insertive-while using stimulants (5 hours prior to, or during, sex) within the last 4 months; stimulants is defined as crystal methamphetamine, cocaine, and MDMA (e.g., ecstasy, molly)
Willing and able to provide written informed consent for study participation

In addition, virtual participants must meet all the below criteria:

Access to a computer/smartphone/tablet that can use video chat (e.g., Zoom or Google Meet)
Provide a mailing address where they can receive a package
Access to stable internet that they can use for more than 2 hours at a time
Have a private place (where no one else can see or hear) where they can complete visits online
Reside within the continental U.S.

You CAN'T join if...

Unable to provide informed consent due to severe mental or physical illness
Concurrent enrollment in another HIV prevention or treatment study (enrollment in a substance treatment program is acceptable
Non-English-speaking
Is currently incarcerated or pending incarceration
Any other medical condition, medical/behavioral intervention, or other condition that, in the opinion of the Site Consortium Project Lead or designee, could interfere with the safety of participants or staff, adherence to study procedures, or compromise interpretation of study results

Locations

University of California, Los Angeles accepting new patients
Los Angeles California 90095 United States
Children's Hospital Los Angeles accepting new patients
Los Angeles California 90027 United States

Lead Scientist at University of California Health

Matthew Mimiaga, ScD, MPH (ucla)
Professor, Epidemiology, Public Health. Authored (or co-authored) 350 research publications

Details

Status: accepting new patients
Start Date: October 2024
Completion Date: December 2028 (estimated)
Sponsor: Westat
ID: NCT06444360
Study Type: Interventional
Participants: Expecting 360 study participants
Last Updated: March 3, 2025